Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL

Quantitative Phase Technology Using Silicon Designed to Visualize Cellular Processes

By BiotechDaily International staff writers
Posted on 16 Oct 2013
A team of scientists has figured out how to quantitatively observe cellular processes taking place on “lab-on-a-chip” devices in a silicon setting.

The new technology should be useful in drug development as well as disease diagnosis, researchers working on the project. In a study published October 2, 2013, in Nature’s online journal Scientific Reports, the investigators reported that it overcame past limitations on quantitative microscopy through an opaque media by working with a new combination of near infrared light and a technique called quantitative phase imaging. The technology is approximately 10-years old and uses shifts in phases of light, not staining techniques, to aid specimen imaging—warranting the term “label-free.”

“To the best of our knowledge, this is the first demonstration of quantitative phase imaging of cellular structure and function in silicon environment,” said Assistant Professor of physics Dr. Samarendra Mohanty, head of the biophysics and physiology laboratory at University of Texas (UT) at Arlington (USA), and corresponding author of the article.

The UT at Arlington and Massachusetts Institute of Technology (MIT; Cambridge, MA, USA) group of scientists was able to study specimens through a silicon wafer in two cases. In one, they achieved full-field imaging of the features of red blood cells to nanometer thickness accuracy. They observed, in another specimen, the dynamic variation of human embryonic kidney cells in response to variations in salt concentration. Dr. Mohanty believes that his group’s current research on near-infrared quantitative-phase imaging can lead to noninvasive, label-free monitoring of neuronal activities.

“Silicon-based microdevices known as labs-on-a-chip are revolutionizing high throughput analysis of cells and molecules for disease diagnosis and screening of drug effects. However, very little progress has been made in the optical characterization of samples in these systems,” said Dr. Bipin Joshi, a recent graduate and lead author of the study. “The technology we’ve developed is well-suited to meet this need.”

Dr. Barman, now an assistant professor at Johns Hopkins University (Baltimore, MD, USA), stated that this study is an excellent example of the type of research he envisages doing, projects driven by needs of the biomedical community and continually pushing the edge of biophotonic technology. “We envision that this significantly expands the visualization possible in silicon based microelectronic and micromechanical devices,” he said.

Related Links:
University of Texas at Arlington
Massachusetts Institute of Technology



Channels

Genomics/Proteomics

view channel
Image: Researchers have generated disease-free stem cells from patients with mitochondrial disease that can be converted into any cell type including neuronal progenitors (left) or heart cells (right). These could potentially be used for future transplantation into patients (Photo courtesy of Salk Institute of Biological Studies).

Methods Developed to Generate Normal Stem Cells from Patients with Mitochondrial Defects

A recent paper described two methods for converting cells from patients with mitochondrial defects into normal pluripotent stem cells that could be induced to differentiate into several different types of tissues.... Read more

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.